References
- Mohamadzadeh M, Pfeiler EA, Brown JB et al. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc. Natl Acad. Sci. USA108(Suppl. 1), 4623–4630 (2011).
- Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev15, 79–94 (2002).
- Schirbel A, Fiocchi C. Inflammatory bowel disease: established and evolving considerations on its etiopathogenesis and therapy. J. Dig. Dis.11, 266–276 (2010).
- Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature Immunol.11, 373–384 (2010).
- Cuffari C. The genetics of inflammatory bowel disease: diagnostic and therapeutic implications. World J. Pediatr.6, 203–209 (2010).
- Tosa M, Negoro K, Kinouchi Y et al. Lack of association between IBD5 and Crohn’s disease in Japanese patients demonstrates population-specific differences in inflammatory bowel disease. Scand. J. Gastroenterol.41, 48–53 (2006).
- Ramasundara M, Leach ST, Lemberg DA, Day AS. Defensins and Inflammation: the role of defensins in inflammatory bowel disease. J. Gastroenterol. Hepatol.24, 202–208 (2009).
- Marks DJ, Harbord MW, MacAllister R et al. Defective acute inflamamtion in Crohn’s disease: a clinial investigation. Lancet367, 668–678 (2006).
- Sewell GW, Marks DJB, Segal AW. The immunopathogenesis of Crohn’s disease: a three stage model. Curr. Opin. Immunol.21, 1–8 (2009).
- Man SM, Zhang L, Day AS, Leach ST, Lemberg DA, Mitchell H. Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohn’s disease. Inflamm. Bowel Dis.16, 1008–1016 (2010).
- Tannock G. The bowel microbiota and inflammatory bowel diseases. Int. J. Inflamm.2010, 954051 (2010).
- Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol.104, 437–443 (2009).
- Uronis JM, Arthur JC, Keku T et al. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm. Bowel Dis.17, 289–297 (2011).
- Pagnin C, Saeed R, Bamias G et al. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc. Natl Acad. Sci USA107, 454–459 (2010).
- Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-β-bearing regulatory cells. J. Immunol.174, 3237–3246 (2005).
- de Moreno de LeBlanc A, del Carmen S, Zurita-Turk M et al. Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterol.2011, 892971 (2011).
- Murai M, Turovskaya O, Kim G et al. Interleukin-10 acts on regulatory T cells to maintain expression of the transcription factor FOXP3 and suppressive function in mice with colitis. Nature Immunol.10, 1178–1185 (2009).
- Hadis U, Wahl B, Schulz O et al. Intestinal tolerance requires gut homing and expansion of FOXP3+ regulatory T cells in the lamina propria. Immunity34, 237–246 (2011).
- Glocker EO, Kotlarz D, Boztug K et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med.361, 2033–2045 (2009).
- Buruiana FE, Solà I, Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev.10, CD005109 (2010).
- Steidler L, Hans W, Schotte L et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science289, 1352–1355 (2000).
- Braat H, Rottiers P, Hommes DW et al. A Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin. Gastroenterol. Hepatol.4, 754–759 (2006).
- Lebeer S, Vanderleyden J, De Keersmaecker SCJ. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat. Rev. Microbiol.6, 171–184 (2010).